Valion Bio, Inc. (VBIO) stock
Close on Nov 13, 2026Market cap $2.20MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.20M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.52
- Dividend yield
- –
- Free cash flow yield
- -667.73%
Fundamentals
- Net income
- -$18.75M
- EPS, diluted
- -$7.77
- Free cash flow
- -$14.67M
- Book value per share
- $1.26
- Diluted shares
- 3M
Trading
- Previous close
- $0.51
- Open
- $0.50
- Day's range
- $0.48 – $0.55
- Volume
- 101,870
- Average volume (20 days)
- 1,006,801
- Beta (5 years)
- 0.66
- 52-week range
- $0.47 – $67.50
- RSI (14 days)
- 23.2
- Volatility (1 year)
- 134.6%
- Relative volume
- 0.07×
- WACC
- 8.4%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | VBIO | S&P 500 | Difference | VBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -65.9% | -3.0% | −62.8 pts | ||
| 3 months | -87.6% | -2.8% | −84.8 pts | ||
| Year to date | -98.5% | +11.5% | −110.0 pts | ||
| 1 year | -99.0% | +13.5% | −112.4 pts | ||
| 3 years | -99.9% | +77.7% | −177.6 pts | -91.7% | +21.1% |
| 5 years | -100.0% | +72.6% | −172.6 pts | -92.6% | +11.5% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Valion Bio filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Valion Bio
Pharmaceutical Preparations
Tivic Health Systems, Inc. operates within the health technology and biopharmaceutical sectors. The company identifies business activities across Biopharma and contract development and manufacturing organization (CDMO) segments, while classifying its Clearup operations within discontinued operations. Through licensing agreements, it engages in biopharmaceutical drug development, including milestones for acute radiation syndrome therapies and neutropenia applications, alongside CDMO-related services.
Company profile, executives and historyValion Bio stock: common questions
What is Valion Bio's stock price?
VBIO closed at $0.53 on Nov 13, 2026, up 4.05% on the day. Over the past 52 weeks it traded between $0.47 and $67.50.
What is Valion Bio's market cap?
Valion Bio was worth $2.20M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is VBIO's P/E ratio?
Valion Bio lost money over the twelve months to Jun 30, 2026 (diluted EPS -$7.77), so it has no meaningful P/E ratio.
Does Valion Bio pay a dividend?
No. Valion Bio has not paid a cash dividend over the last twelve months.
How has VBIO stock performed over the past year?
Including dividends, VBIO returned -99.0% over the past year, against +13.5% for the S&P 500.
How many VBIO shares are sold short?
0M shares were sold short at the latest FINRA report, 5.84% of the float, or 1.0 days of average trading volume.
Who are Valion Bio's competitors?
Companies most similar to Valion Bio by business, industry and size include XTLB, SCNX, GDTC, ABVC, XCUR.
See a number that looks wrong?